Method of providing pirfenidone therapy to a patient
View Patent ↗The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
1. An initial dose escalation regimen method for providing pirfenidone therapy to a patient for the treatment of idiopathic pulmonary fibrosis, comprising:
providing pirfenidone to a patient at a first oral daily dosage of 801 mg for days one to seven of the dose escalation regimen;
providing a second oral daily dosage of 1602 mg pirfenidone for days eight to fourteen of the dose escalation regimen; and
providing a third oral daily dosage of 2403 mg pirfenidone for at least day fifteen of the dose escalation regimen, wherein the patient is provided pirfenidone for the treatment of idiopathic pulmonary fibrosis.
2. The method of claim 1 , further comprising instructing the patient to administer the dosage with food.
3. The method of claim 1 , wherein each daily dosage is provided as a plurality of dosage forms comprising sub-daily dosages.
4. The method of claim 3 , wherein each daily dosage is split into three divided doses provided three times a day.
5. The method of claim 1 , wherein each oral daily dosage is provided in capsule form.
6. The method of claim 5 , wherein each capsule comprises 267 mg of pirfenidone.
7. A method of reducing the incidence of photosensitivity reaction adverse events in a patient receiving pirfenidone therapy for the treatment of idiopathic pulmonary fibrosis, comprising use of an initial dose escalation regimen comprising the steps of:
providing pirfenidone to the patient at a first oral daily dosage of 801 mg of pirfenidone for days one to seven of the dose escalation regimen; providing a second oral daily dosage of 1602 mg pirfenidone for days eight to fourteen of the dose escalation regimen; and providing a third oral daily dosage of 2403 mg pirfenidone for at least day fifteen of the dose escalation regimen.
8. The method of claim 7 , further comprising instructing the patient to administer the dosage with food.
9. The method of claim 7 , wherein each daily dosage is provided as a plurality of dosage forms comprising sub-daily dosages.
10. The method of claim 9 , wherein each daily dosage is split into three divided doses provided three times a day.
11. The method of claim 7 , wherein each oral daily dosage is provided in capsule form.
12. The method of claim 11 , wherein each capsule comprises 267 mg of pirfenidone.
13. In a method of treating a patient with pirfenidone for idiopathic pulmonary fibrosis, the improvement comprising: reducing the incidence of photosensitivity reaction adverse events in the patient receiving pirfenidone therapy by use of an initial dose escalation regimen comprising providing pirfenidone to a patient at a first oral daily dosage of 801 mg of pirfenidone for days one to seven of the dose escalation regimen; providing a second oral daily dosage of 1602 mg pirfenidone for days eight to fourteen of the dose escalation regimen; and providing a third oral daily dosage of 2403 mg pirfenidone for at least day fifteen of the dose escalation regimen.
14. The method of claim 13 , further comprising instructing the patient to administer the dosage with food.
15. The method of claim 13 , wherein each daily dosage is provided as a plurality of dosage forms comprising sub-daily dosages.
16. The method of claim 15 , wherein each daily dosage is split into three divided doses provided three times a day.
17. The method of claim 13 , wherein each oral daily dosage is provided in capsule form.
18. The method of claim 17 , wherein each capsule comprises 267 mg of pirfenidone.
19. The method of claim 13 , comprising reducing the incidence of photosensitivity reaction adverse events to about 12%.